ArticleBiochemistry and biophysics reports2025
Association between anti-nuclear antibody (ANA) positivity and autoimmune thyroid disease markers in a general examination population.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-nuclear antibodies (ANA), key biomarkers in systemic autoimmune diseases (AD), have been reported at higher levels in patients with autoimmune thyroid diseases (AITD), including Hashimoto's thyroiditis (HT) and Graves' disease (GD). However, a systematic evaluation of the association between ANA positivity and AITD serological markers (TPOAb, TgAb, TSH, fT3, fT4) in the general population is lacking. Methods: This retrospective cohort study analyzed data from 7556 individuals undergoing routine health examinations at our hospital. ANA was detected by indirect immunofluorescence. Thyroid markers were measured via chemiluminescence immunoassay. Participants were stratified by predefined clinical cut-offs for each marker. Associations between marker levels and ANA positivity, pattern and titer were analyzed respectively. Results: ANA positivity rates increased significantly with higher levels of TPOAb (≤34 IU/ml: 6.03 %, 34 IU/ml-100 IU/ml: 13.03 %, ≥100 IU/ml: 16.50 %; P < 0.001) and TgAb levels (≤115 IU/ml: 5.84 %, 115IU/ml-500IU/ml: 18.10 %, ≥500IU/ml: 19.29 %; P < 0.001). Logistic regression confirmed that with the increase in TPOAb and TgAb levels, the positive risk of ANA increased by approximately 1.6-fold and 2.7-fold respectively. TSH ≥4.2 mIU/L showed marginally increased ANA positivity (OR = 1.14, 95 % CI = 0.47-2.75). No significant associations were found with fT3 or fT4. AC-4/5 (speckled, 37.64 %) and AC-1 (homogeneous, 27.95 %) were dominant ANA patterns; the AC-1 prevalence increased with higher TPOAb/TgAb levels. Conclusion: Elevated thyroid autoantibodies (TPOAb, TgAb) are strongly associated with increased ANA positivity risk, suggesting a link between thyroid-specific and systemic autoimmunity. Thyroid hormone levels showed minimal association. Patients with high TPOAb/TgAb, especially females, may benefit from ANA screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.